Effects of interleukin-1 beta on thyrotropin secretion and thyroid hormone uptake in cultured rat anterior pituitary cells by Wassen, F.W.J.S. (Frank) et al.
Vol 137. No. 5 
I’rrntcd ,n U.S.A 
Effects of Interleukin-IP on Thyrotropin Secretion and 
Thyroid Hormone Uptake in Cultured Rat Anterior 
Pituitary Cells* 
F. W. J. S. WASSEN, E. P. C. M. MOERINGS, H. VAN TOOR, E. A. DE VREY, 
G. HENNEMANN, AND M. E. EVERTS: 
Department of Internal Medicine III, Erasmus University Medical School, Rotterdam, The Netherlands 
ABSTRACT 
The effects of interleukin-lp (IL-lfi) and tumor necrosis factor-a 
(TNFtu) on basal and TRH-induced TSH release, and the effects of 
IL-lfl on the uptake of I ““I IT,, and [ ““IIT,, and on nuclear binding of 
I ‘2r,IlT:( were examined. Furthermore, the release of other anterior 
pituitary hormones in the presence of IL-lfi was measured. Anterior 
pituitary cells from male Wistar rats were cultured for 3 days in 
medium containing 10% FCS. Incubations were performed at 37 C in 
medium with 0.5% BSA for measurement of [‘““IlT,, uptake and with 
0.1% BSA for measurement of I “’ IIT, uptake. Exposure to IL-l/3 (1 
pn~-1 nhl) or TNFtv (100 PM) for 2-4 h resulted in a significant decline 
in TSH release, which was almost 50% (P < 0.05) for 1 n%i IL-lfi and 
24% (P < 0.05) for 100 P-M TNFtu. Measurement of other anterior 
pituitary hormones (FSH, LH, PRL, and ACTH) in the same incu- 
bation medium showed that IL-lfi did not alter their release. When 
the effects of IL-lp (1 ~15-1 nM) and TNFtv (100 pb~) on TRH-induced 
TSH release were measured in short term experiments, the inhibitory 
effects had disappeared. The addition of l-100 n%i octreotide, a so- 
matostatin analog, resulted in a decrease in TRH-induced TSH re- 
lease up to 33% of the control value (P i 0.05). Exposure to dexa- 
methasone (1 nM to 1 FM) affected basal and TRH-induced TSH 
release similar to the effect ofIL-l/3. The 15-min uptake of [ ““I IT:, and 
[““IIT,, expressed as femtomoles per pM free hormone, was not af- 
fected by the presence of IL-l/3 (l-100 ply). When IL-lp (100 pnl) was 
present during 3 days of culture, TSH release was reduced to 88 t 2(/ 
of the control value (P < 0.05). This effect was not associated with an 
altered I ‘ZiIIT:, uptake (15 min to 4 h) or with any change in nuclear 
T:, binding. We conclude that 1) IL-10 decreases TSH release by a 
direct action on the pituitary; 2) this effect is not due to elevated 
thyroid hormone uptake or increased T:, nuclear occupancy; 3) IL-lb 
does not affect TRH-induced TSH release or the release of other 
anterior pituitary hormones; and 4) TNFn affects basal and TRH- 
induced TSH release in the same way as IL-lp. (EndocrinoZog,y 137: 
1591-1598, 1996) 
D URING SYSTEMIC illness, striking changes occur in serum thyroid parameters, a condition referred to as 
nonthyroidal illness (NTI). Most prominent are the low T, 
and elevated rT, together with a serum TSH level that is 
unaltered or even diminished (1, 2). Both the impaired me- 
tabolism of rT, and the reduced conversion of T, to T, are 
probably caused by a decrease in type I deiodinase activity 
(3). In addition, inhibition of transport of thyroid hormones 
into the liver contributes to the low serum T, level (4). Re- 
cently, a number of compounds that inhibit the transport of 
T, into peripheral tissues have been identified (5, 6). How- 
ever, as these same compounds did not affect thyroid hor- 
mone transport into the pituitary (7), the mechanism pre- 
venting the serum TSH level from rising remains unknown. 
In recent studies, a role for cytokines, especially interleu- 
kin-l (IL-l), IL-6, and tumor necrosis factor-a (TNFa), in the 
pathogenesis of NT1 was suggested (g-10). Cytokines are 
soluble peptides, mainly produced by macrophages and 
lymphocytes after immune challenge or inflammation, and 
are known for their regulatory role in the immune response. 
However, they are now also regarded as important factors 
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that intimately link the immune and neuroendocrine systems 
(11). Attempts to prove that the decrease in TSH level in 
animals treated with cytokines was due to a central effect (i.~. 
diminished production of TRH) have not produced clear 
evidence (12,13). Also, IL-1 receptors and IL-1 receptor mes- 
senger RNA were found in anterior pituitary cells of mice 
(14-16) and in the anterior pituitary tumor cell line AtT-20 
(17, 18). Finally, a recent in zjitm study with anterior pituitary 
cells reported an effect of TNFa on TSH release (19). Taken 
together, these findings suggest that cytokines, and in par- 
ticular IL-l, could have a direct effect on the pituitary. 
We, therefore, examined the effects of IL-lp and TNFa on 
TSH release of cultured anterior pituitary cells. Also, cellular 
T, and T, uptake, nuclear T, occupancy, and release of other 
anterior pituitary hormones in the presence of IL-l/3 were 
determined. This was performed to investigate whether IL- 
lb-induced changes in TSH release were related to altered 
thyroid hormone uptake and nuclear T, occupancy and 
whether IL-l/3 affected the thyrotropic cells specifically or the 
effect was the result of a more general action of IL-10 on the 
endocrine cells of the anterior pituitary. Furthermore, as both 
somatostatin and cortisol are important regulators of TSH 
secretion in response to stress or disease (20), we also tested 
the effects of octreotide (a somatostatin analog) and dexa- 
methasone. 
Serum concentrations of IL-l/? in healthy subjects, in 
patients with sepsis or rheumatoid arthritis, and after endo- 
toxin infusion were all in the picomolar range (21, 22). 
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However, as local IL-l/3 production in the pituitary has been 
found (23), the actual tissue concentration may be higher 
than the measured serum values. Furthermore, the effects of 
IL-l/3 on pituitary hormone release irr vitro were most prom- 
inent at concentrations ranging from 1 PM to 1 nM (24), 
whereas cytotoxicity was first observed at an IL-lb concen- 
tration of 10 IIM (25). Therefore, we used IL-lp concentrations 
varying from 1 pM to 1 nM. 
Materials and Methods 
Materials 
All solutions used for cell isolation and cell culture were obtained 
from Life Technologies Europe (Breda, The Netherlands), with the ex- 
ception of human serum albumin (Central Laboratory of the Red Cross 
Blood Transfusion Service, Amsterdam, The Netherlands), dispase 
(grade 11; Boehringer, Mannheim, Germany), and fungizone (Bristol- 
Myers Squibb, Woerden, The Netherlands). Culture dishes (48 wells) 
were obtained from Costar (Cambridge, MA). Human recombinant 
IL-lp and human recombinant TNFu were purchased from Genryme 
Corp. (Cambridge, MA). Octreotide was purchased from Sandoz (Base], 
Switzerland), CRF from UCB (Brussels, Belgium), and TRH from Ho- 
cchst (Frankfurt am Main, Germany). Piperazine-NJ’-bis-[Z-ethane sul- 
fonic acid], HEFES, N,N-bis-[2-hydroxyethyl]2-aminocthane sulfonic 
acid, BSA (fraction V), dexamethasone, and N-nitro-o-arginine methyl 
ester (L-NAME) were obtained from Sigma Chemical Co. (St. Louis, 
MO). L-T~ (T,) was purchased from Henning Berlin (Berlin, Germany). 
[3’,5’-“‘I]T., (1500 pCi/F*g) and [3’-‘?]T, (3070 kCi/pg) were obtained 
from Amersham International (Aylesbury, UK). Ingredients for the rat 
TSH RIA were kindly provided by the NIDDK (Bethesda, MD). Seph- 
adex LH-20 and G-25 were obtained from Pharmacia (Uppsala, Sweden). 
All other reagents were of the highest purity available. 
Animals 
All experiments were performed using male Wistar rats, weighing 
200-220 g. The animals had free access to food and water and were kept 
in a controlled environment (21 C) with constant day length (12 h). 
Cell culture 
Animals (n = 12-16 for each experiment) were killed between 0900- 
0930 h by decapitation. The pituitary glands were removed within 5 min, 
the neurointermcdiate lobe was discarded, and the anterior lobes were 
collected in calcium- and magnesium-free Hanks’ Balanced Salt Solution 
supplemented with IO g/liter human serum albumin, penicillin (lo5 
U/liter), fungizone (0.5 mg/liter), and sodium bicarbonate (0.4 g/liter). 
Anterior pituitary cells were dissociated with dispase (final concentra- 
tion, 2.4 X 1 O1 U/liter), as described in detail previously (26). From each 
pituitary, 1.5 x 10” cells were obtained, and the viability of the cells, 
determined by trypan blue exclusion, was greater than 90%. 
The cells were cultured at 37 C in a water-jacketed incubator with 5% 
CO, at a density of 4-8 x 10’ cells/ well in 4%well culture dishes. The 
cells were attached to the wells after2 days of culture. On day 3, the cells 
were used for experiments. The culture medium consisted of MEM with 
Earle’s salts supplemented with nonessential amino acids, sodium pyru- 
vate (1 mmol/liter), 10% FCS, penicillin (10’ U/liter), fungizone (0.5 
mg/ liter), L-glutamine (2 mmol/liter), and sodium bicarbonate (2.2 g/ li- 
ter; pH 7.4) (26-2X). 
Hormone release and cellular content 
The culture medium was removed and centrifuged (2000 X g), and 
the supernatant was frozen until hormone determination. The incuba- 
tion medium was identical to the culture medium, except that the FCS 
was replaced by 0.5% BSA. The effects of IL-1 p and other compounds 
on basal release of TSH, LH, FSH, ACTH, and PRL were measured after 
2-4 h of incubation (A), effects on TRH-stimulated TSH release were 
examined during 2-h exposure after 2 h of preincubation (B), and the 
possible role of nitric oxide (NO) in the effect of IL-lp on TSH release 
was examined in 4-h experiments by simultaneous incubation of IL-lp 
with the NO synthase inhibitor L-NAME (C) all at 37 C. 
For A and C, cells were washed once with incubation medium and 
incubated for 2-4 h with TNFcv (100 PM), octreotide (100 PM), dexa- 
methasone (I no to 1 F~LI), IL-ID (1 p” to I 11~) without or with L-NAME 
(0.05-0.5 mM), or TRH (100 nbi). After incubation, the medium was 
removed, centrifuged (2000 X g), and stored at -20 C. 
For B, TRH-stimulated TSH release was examined after preincubation 
for 2 h without or with TNFa (100 PM), IL-lfl (1 PM to 1 IBM), dexa- 
methasone (1 nM to 1 +M), or octrcotidc (l-100 nM). The preincubation 
medium was discarded, and incubation was continued for 2 h without 
or with TRH (100 nM) and the additions described above. The TSH 
rcsponsc to TRH was used to ascertain the presence of active thyrotrophs 
in the preparation. As freshly isolated anterior pituitary cells were used 
for every experiment, and therefore, the quality of cells could vary 
between experiments, the magnitude of the TSH response to TRH was 
variable. However, in every experiment a significant increase in TSH 
release after the addition of TRH was observed. For determination of the 
cellular TSH content, 0.5 ml incubation medium was added to the wells. 
The cells were scraped from the wells with a rubber policeman, and the 
wells were sonicated twice for 30 set each time. The extracts were 
removed, and the wells were washed with 0.5 ml medium. The two 
fractions were then combined (volume of cell extract, 1.0 ml) and cen- 
trifuged (2000 X s) at room temperature, and the supernatant was frozen 
until further analysis. 
Hormone determinations 
TSH, LH, FSH, and PRL were determined by RIA as described pre- 
viously (26-29). ACTH release from rat pituitary cells was estimated by 
an immunoradiometric assay for determination of human ACTH in 
plasma (CIS Biointernational; Gif-sur-Yvette, France). 
Cellular [““I]T, and [12,51]T,f uptake 
Cellular uptake experiments were performed with variable incuba- 
tion times (15 min to 4 h). After removal of the culture medium, cells 
were preincubated with incubation medium. This medium was identical 
to the culture medium, except that the FCS was replaced by 0.5% BSA 
when uptake of [“iI]T, (50,000 cpm; 50 PM) was measured or with 0.1% 
BSA when uptake of [“‘I]T, was determined (100,000 cpm; 175 PM). 
Preincubation (0.25 ml) was carried out for 30 min at 37 C in the presence 
or absence of various concentrations of IL-Ip (l-100 PM). Incubation 
started by adding 10 ~1 [‘2iI]T, or [‘?]T, directly to the preincubation 
medium and lasted 15 min. In the time-course experiments, IL-lp (100 
PM) was added to the culture medium. The experiments were performed 
as described above, except that the prcincubation medium did not con- 
tain any additions and was discarded after 30 min. Thereafter, 0.25 ml 
incubation medium containing [IZSI]T, was added to the cells for 15 min, 
1 h, or 4 h. 
Incubations lasting for more than 1 h were performed at 37 C in 
humidified air with 5% CO,. Incubations of shorter duration took place 
in a 37 C incubation chamber on a rotating device without CO?. There- 
fore, the NaHCO, in the incubation medium was replaced by ‘an equimo- 
lar amount of HEPES (8.9 mM), piperazine-N,N’-bis+ethane sulfonic 
acid] (10.6 mM), and N,N-bis-[2-hydroxyethyl]2-aminoethnne sulfonic 
acid (11.2 mM). 
After incubation, the medium was removed, and the cells were 
washed once with 7 ml ice-cold saline to remove the tracer not bound 
to the cells. Cells were dissolved in 1 ml 0.1 N NaOH and were counted 
for “‘1 activity in a lh-channel y-counter (NE 1600, Nuclear Enterprises, 
Edinburgh, Scotland). The amount of [‘?]T, or [‘?]T., taken up by the 
cells was expressed as a percentage of the added radioactivity (percent 
dose). The procedure described above was also applied to incubations 
without cells (blanks). All results were corrected for the radioactlvity 
observed in the blanks. 
Nuclear binding of [“,I]T3 
After incubation, cells were washed with I ml ice-cold saline (0.9% 
NaCI). All of the following actions were performed on ice. Cells were 
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scraped from the wells with a rubber policeman in 1 ml PBS and counted 
for 1 min. Then, they were centrifuged (300 x s; 4 C; 7 min) and counted 
(1 min) while 1 ml PBS-0.5% Triton X-100 was added to the cell pellet, 
as previously described (30). Cells were vortexed for 2 min and ccntri- 
fuged (900 X s; 4 C; 5 min) to reveal the nuclei. The nuclear pellet was 
counted for 5 min. 
DNA determination 
The DNA content of cells or nuclear pellets was determined using a 
modification (31) of the fluorescence technique described by Downs and 
Wilfinger (32). 
Free hormone fraction 
Calculation of the free T, (FT,) or free T, (FT,) concentration was 
based on determination of the free fractions by equilibrium dialysis (33). 
In medium containing 0.5% BSA, the FT, fraction was 3.78 t 0.15% (n 
= 4), whereas the FT, fraction was 3.60 2 0.17% (n = 4) in medium 
containing 0.1% BSA. The addition of variable concentrations of IL-l/3 
(I and 100 PM) altered the free fractions of both iodothyronines only 
slightly, to 3.55 5 0.02% (n = 4) and 3.50 t 0.04% (n = 4) for the FT, 
fraction and to 3.76 2 0.37% (n = 4) and 3.58 ? 0.45% (n = 4) for the FT, 
traction. Nevertheless, the net cellular uptake of radiolabeled T, and T, 
was corrected for these slight changes in free hormone concentrations 
by expressing the data in femtomoles per PM free hormone. 
Statistics 
The statistical significance of the effects of the various compounds 
tested on TSH, LH, FSH, PRL, and ACTH release; the uptake of [‘?]T, 
and [“‘IIT,; and the nuclear binding of radiolabeled T, was calculated 
by Student’s f test for unpaired observations or Duncan’s test for a 
repeated measure design. P i 0.05 was regarded as statistically signif- 
icant. 
Results 
Short term effects of cytokines, dexamethasone, 
and octreotide 
BCWI~ TSH ~&VW. To determine the effects of IL-lb, TNFq 
dexamethasone, or octreotide on basal TSH release, these 
compounds were added during 2- to 4-h incubations. Ad- 
dition of IL-lp (1 PM-I nM) for 4 h resulted in a dose-de- 
pendent decrease in TSH release; the highest concentration 
produced a maximum inhibitory effect of almost 50% (P < 
0.05). The cellular TSH content showed no significant change, 
nor did the total TSH, expressed as the sum of medium and 
cells (Table 1). This indicated that IL-l/3 was not toxic to the 
cells, which was also confirmed by measurement of the cel- 
lular DNA content after 4 h of incubation. The DNA content 
(micrograms per well) was 1.64 + 0.03 (n = 3) in the presence 
of 1 nM IL-lp and 1.51 i- 0.05 (n = 6) in control cells. Exposure 
to 100 nM TRH resulted in a significant rise (38%; P < 0.05) 
in TSH release, without a significant change in the cellular or 
total TSH content. The addition of another major cytokine, 
TNFcK, at a concentration of 100 PM reduced basal TSH re- 
lease by 24 + 5% (n = 9; P < 0.05). 
In two experiments, the effects of dexamethasone (1 nM to 
1 PM) and octreotide (100 IIM) were examined after 2 h of 
incubation. Addition of 1 IIM dexamethasone resulted in a 
decline in TSH release of approximately 20% (P < 0.05), an 
effect similar to that observed at the highest dexamethasone 
concentration of 1 PM (24%; P < 0.05; Fig. 1). Octreotide, 
however, did not affect basal TSH release at the concentra- 
tion tested (not shown). 
TRH-ilrduced TSH rrlense. In two experiments, the same com- 
pounds as those used above were tested for their effects on 
TRH-induced TSH release during short (2-h) exposure. Data 
were expressed as a percentage of the control values (TRH 
alone). Figure 2A shows that IL-lp had no effect on TRH- 
stimulated TSH release at concentrations varying from 1 PM 
to 1 nM. TNFa at a concentration of 100 PM also did not alter 
TRH-induced TSH release (n = 6; not shown). The stimula- 
tion of TSH release by TRH in these experiments was more 
than 400% (not shown), indicating that the anterior pituitary 
cells responded well to TRH. Dexamethasone did not affect 
TRH-stimulated TSH release at the concentrations tested (10 
nM to 1 PM; Fig. 2B). However, octreotide was a very potent 
inhibitor of the stimulatory effect of TRH on TSH release at 
any concentration tested; the lowest (1 nM) produced a max- 
imum inhibition of 67% (P < 0.05; Fig. 2C). 
Relensc of other pifuifary IIOY~~KVWS. In the incubation medium 
from two of the experiments shown in Table 1, FSH and LH 
were also determined (Table 2). Cells were incubated for 4 h 
without or with IL-lfi in concentrations ranging from l-100 
PM. Addition of the lowest concentration showed a signifi- 
cant decrease in hormone release for both FSH and LH (P < 
0.05). However, at higher concentrations this inhibitory effect 
of IL-lfl disappeared, and hormone release was not different 
from the control values. Incubation with TRH did not affect 
FSH or LH release. 
The effect of IL-16 (l-100 PM) on ACTH release was de- 
TABLE 1. Effects of variable concentrations of IL-lp on TSH release and cellular content of anterior pituitary cells and total TSH as the 
sum of TSH content in medium and cells 
Exp conditions 
No additions c 12) 
+ 1 p>1 IL-1p (12) 
+ 10 pnl IL-1p (12) 
+ 100 pa1 IL-lfi (12, 
+ 1 n&f IL-lb (6) 
+ 100 nR1 TRH (10) 
Medium 
6.37 k 0.46 
4.58 k 0.33” 
4.86 2 0.28” 
4.33 -+ 0.13” 
3.40 2 0.14” 
8.81 + 0.42” 
TSH content (ng) 
Cells Total 
34.88 i- 1.89 41.25 -t 1.98 
34.10 2 1.88 38.68 2 1.91 
32.63 5 2.30 37.49 + 2.40 
31.42 -c 2.48 35.75 5 2.47 
32.49 2 1.25 35.89 i 1.32 
28.21 i- 1.68 37.02 5 1.87 
Data show the mean of6-12 observations in 2-4 experiments. Anterior pituitary cells (400,000 cells/well) were cultured for 3 days in medium 
containing 10% FCS. After removal of the culture medium, cells were incubated for 4 h without or with addition of IL-l/J or TRH at the 
concentrations shown above. TSH was measured in medium and cells by RIA. Also, the total TSH content was calculated as the sum of medium 
and cells. 
” P < 0.05 US. no additions. 
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FIG. 1 The effect of dexamethasone on basal TSH release. Anterior 
pituitary cells were cultured for 3 days at a density of 400,000 cells/ 
well. Cells were preincubated for 2 h in incubation medium containing 
0.5% BSA. This was followed by incubation for 2 h in medium without 
or with variable concentrations of dexamethasone. TSH released in 
the presence of dexamethasone is expressed as a percentage of the 
control value, i.e. TSH release in the absence of any additions. Bars 
show the mean i SE ofthree to six observations from two experiments 
with control values of 5.7 5 0.1 (n = 3) and 9.6 5 0.6 (n = 3) ng 
TSH/well respectively. ‘ti, P < 0.05 US. no additions. 
termined after 4 h of incubation and compared with that of 
CRF (10 nM). The addition of CRF resulted in a 5-fold stim- 
ulation of ACTH release, from 4 + 1 q/ml (n = 3) to 18 + 
1 rig/ml (n = 4) (P < 0.05). The presence of IL-1P did not 
change ACTH release at any of the concentrations tested (not 
shown). The addition of CRF did not affect TSH release (not 
shown), whereas the presence of 100 PM IL-l@ resulted in a 
decline in TSH release of approximately 25% (P < 0.05), i.r. 
an effect similar to that described above. 
Finally, the incubation medium of one of the experiments 
presented in Table 1 was used to measure PRL levels. PRL 
release in the absence of any addition was 1200 -+ 50 q/ml 
(n = 3), and the presence of IL-l/3 did not alter PRL release, 
which was 1260 + 60,130O + 50,133O ? 40, and 1300 5 270 
rig/ml with 1, 10, 100, and 1000 PM IL-lp, respectively (n = 
3 for all). 
lllitirrl upfcrke of [““IIT, alzti [“il]T,. A series of experiments 
was performed to study the effect of IL-1p on the initial 
uptake of [“‘I]T, and [12’I]T, at the level of the pituitary 
plasma membrane, i.e. after 15 min of incubation. [1251]T, 
uptake was measured in medium containing 0.5% BSA, 
whereas [12’I]T, uptake was determined in medium with 
0.1% BSA. This was performed to increase the free hormone 
fraction of T, and, thus, the availability of T, to the pituitary 
cells (34). 
The 15-min uptakes of [ ‘251]T, and [1251]T, expressed per 
PM free hormone were 0.101 2 0.008 (n = 20) and 0.027 ? 
0.003 (n = I5), respectively, in good agreement with previous 
results obtained with the same cell preparation (34,35). Nei- 
ther [“‘IIT uptake nor that of [1251]TA was affected by IL-lp 
in the concentration range l-100 PM (Fig. 3). 
Long term effects of IL-lp on basal TSH release and 
[““I/T, uptake 
TSH relense. To examine the effect of long term exposure to 
IL-l& pituitary cells were cultured in the presence of 100 pM 
lnterleukin 1 beta (PM) 
i 0 10 100 1000 
E Dexamethasone (nh4) 
150 I 
t 
C 
100 
50 
ILam 
* * * 
0 
0 1 10 100 
Octreotide (nM) 
FIG. 2 Effects ofIL-l/J (A), dexamethasone (B), and octreotide (0 on 
TRH-induced TSH release. Anterior pituitary cells were cultured for 
3 days at a density of 400,000 cells/well. Thereafter, cells were pre- 
incubated for 2 h in incubation medium in the presence or absence of 
variable concentrations of IL-10 (A), dexamethasone (B), or octreotide 
(Cl. Incubations were performed by adding TRH (100 nnl) alone or 
together with the compounds mentioned above to the cells and lasted 
2 h. TSH released in the presence of TRH and variable concentrations 
of IL-l& dexamethasone, or octreotide was expressed as a percentage 
of the TSH released in the presence of TRH alone. Bars represent the 
mean + SE of three to six observations from two experiments, with 
basal TSH values of 3.2 t 0.1 (n = 2) and 7.8 5 1.0 (n = 3) rig/well. 
:/:, P < 0.05 L’S, controls. 
IL-l/3, which was added from day 0. As in the short term 
experiments, the effect of IL-lp was compared with those of 
TRH (1 nM) and octreotide (1 nM). Figure 4 shows the effects 
of these compounds on TSH release. Long term exposure to 
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TABLE 2. Effect of 4-h incubation with variable concentrations of 
IL-16 on FSH and LH release from anterior pituitary cells 
Exp conditions 
Hormone release (ng) 
FSH LH 
No additions (6) 5.99 ? 0.58 8.59 2 1.69 
1 p&r IL-lfi (6) 4.49 + 0.31” 5.45 i- 0.59" 
lo pM IL-lp (6) 5.49 k 0.56 6.53 2 0.67 
50 pnf IL-16 (6) 5.01 i- 0.36 6.70 i- 0.73 
100 P-M IL-16 (6) 4.90 k 0.22 8.23 -c 0.58 
100 n>f TRH (6) 4.97 -+ 0.17 7.62 2 0.68 
Data show the mean 2 SE of six observations in two experiments. 
Anterior pituitary cells were cultured for 3 days in medium containing 
10% FCS. Then culture medium was removed, and cells were incu- 
bated for 4 h in medium without or with variable concentrations of 
IL-16. Thereafter, FSH and LH were measured in medium by RIA. 
” P < 0.05 us. no additions. 
m T3 uptake 0 T4 uptake 
1 
1 
0 
'n 
3 
0 1 10 100 
lnterleukin 1 beta (PM) 
FIG. 3 Uptake of [“‘I IT,, and 1 ‘““IlT, by male anterior pituitary cells 
in the presence of IL-16 Cells were cultured for 3 days at a density 
of 500,000 cells/well. Thereafter, culture medium was removed, and 
cells were washed once with incubation medium containing0.5% BSA 
when [‘““IIT,, was measured and O.lQ BSA in the case of [““IIT,. 
Then, cells were preincubated for 30 min in incubation medium with- 
out or with various concentrations of IL-l/$ whereas incubation 
started by adding 10 ~1 [ ‘““I IT:, (50,000 cpm/well) or 1 I251 IT, (100,000 
cpm/weK directly to the preincubation medium. Uptake of both trac- 
ers, measured for 15 min, is expressed per PM free hormone. Bars 
represent the mean t SE of 9-20 observations from 3-7 experiments. 
None of the differences in 1”’ I IT,, uptake was statistically significant. 
IL-l/3 reduced TSH release of the pituitary cells to 88 + 2% 
(P < 0.05) of the control value (Fig. 4, secorln colur~zrl). Ad- 
dition of TRH stimulated TSH release by 27 -t 7% (P < 0.05), 
indicating the presence of active thyrotropic cells. Octreotide 
reduced TSH release to 91 + 3% (P < 0.05) of the control 
value (Fig. 4, losf colur~rrr). 
/“‘IIT, y~takc. To examine the effect of long term exposure 
to IL-lp on the cellular uptake of T,, anterior pituitary cells 
were cultured without or with 100 PM IL-lb. The addition of 
100 PM IL-1P resulted in a decrease in TSH release of 15% 
compared with the control value (n = 15; P < 0.05). The time 
course of [“‘I]TR uptake was measured at 15 min, 1 h, and 
4 h of incubation (Fig. 5). The uptake of radioactive T, in 
pituitary cells cultured in the presence or absence of IL-l/3 
showed a steep rise up to 1 h of incubation and then leveled 
off. In contrast with the effect on TSH release, IL-l/3 did not 
affect [‘ZiI]TI uptake at any time measured (Fig. 5). 
CTRL IL-l TRH OCT 
FIG. 4 Effect of long term exposure to IL-lp (100 PM), TRH (1 nM1, 
and octreotide (OCT; 1 nW on TSH release by anterior pituitary cells 
(800,000 cells/well). Compounds were added on day 0 to the culture 
medium. After 3 days of culture, the medium was removed, and TSH 
release was measured. Data represent the mean of 12-17 observa- 
tions from 2 independent experiments and are expressed as a per- 
centage of the control value, i.e. cells cultured in the absence of any 
additions. Absolute control values were 99.5 ? 1.6 (n = 9) and 103.5 
2 7.1 (n = 8) ng TSWwell, respectively. ‘I’, P < 0.05 us. no additions. 
d 
/x 
Time (h) 
FIG. 5 Effect of long term exposure to IL-16 on the cellular uptake 
of l”“IlT,,. Rat anterior pituitary cells were cultured for 3 days in 
presence (Gl or absence (0) of 100 PM IL-l& After 3 days, culture 
medium was removed, and cells were preincubated for 30 min in 
incubation medium containing 0.5% BSA. This was followed by in- 
cubation in the same medium with 1 ‘““IIT:, (50,000 cpmiwell) for 15 
min, 1 h, and 4 h. Uptake is expressed as a percentage of the total 
added radioactivity (percent dose). Data represent the mean -t SE of 
five or six observations from two independent experiments. 
Nuclear hiding of[““l]T,. We also examined whether IL-lp 
influenced nuclear binding of [ ‘2sI]T,. Anterior pituitary cells 
(800,000 cells/well) were cultured for 3 days in the presence 
or absence of 100 PM IL-lp. Thereafter, cells were incubated 
for 2 h with [‘251]T3 in the absence or presence of 10 FM T,. 
In Table 3, the radioactivity detected in cellular and IILI- 
clear pellets is shown. Again, IL-lp did not change cellular 
uptake or alter nuclear binding of [‘?]T,. The addition of 10 
PM T, during incubation decreased cellular [ ‘251]Ti uptake by 
approximately 55X, whereas nuclear uptake of the tracer was 
completely inhibited. The lnst co/u~rl of Table 3 shows the 
DNA content of the nuclear pellets, which was similar for the 
three culture/incubation conditions. When nuclear bound 
[“‘I]T, was expressed per pg DNA, the value for the control 
incubations was 0.42 + 0.04 (n = 4), and for the cells cultured 
in presence of IL-Ip, the value was 0.24 5 0.01 (n = 3; 
P < 0.05). 
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TABLE 3. Effects of presence of IL-la during culture on cellular and nuclear bound I ““I IT,, and DNA content in cultured anterior 
pituitary cells 
Culture conditions Exp conditions 
No additions (4) No additions 
No additions (4) + 10 FLM T:, 
+ 100 p>1 IL-10 (3) No additions 
/ ‘=I IT ( radmctmy t% dose) 
Cell pellel Nuclear pellet 
2.17 t 0.12 0.47 2 0.08 
0.95 2 0.09” 0.03 i 0.01” 
2.20 k 0.10 0.32 i 0.01 
DNA content nuclei IP~J 
1.11 -t 0.08 
1.19 2 0.13 
1.34 k 0.09 
Data show the mean -t SE of three or four observations in a single experiment. Anterior pituitary cells were cultured for 3 days at a density 
of 800,000 cells/well. IL-lp was added on day 0 to the culture medium. After preincubation for 30 min, cells were incubated for 2 h in medium 
containing 0.5% BSA and I I” IIT,, (100,000 cpm) in the absence or presence of 10 fin1 unlabeled T:,. Cells were scraped from the wells with 2 
X 0.5 ml ml ice-cold PBS. After centrifugation, the cell pellet was counted. The nuclear pellet was obtained after the addition of Triton X-100, 
followed by centrifugation. For further details, see Materials and Methods. 
I’ P C( 0105 US. noadditions. 
Role of NO in the effect of IL-l/3 on TSH release 
In two experiments we investigated the role of NO in the 
effect of IL-lp on basal TSH release. Anterior pituitary cells 
were incubated for 4 h with 100 PM IL-lp alone or together 
with the NO synthase inhibitor L-NAME at concentrations of 
0.05 and 0.5 mM. The inhibitory effect of 100 PM IL-lp on TSH 
release (38%) was similar to that observed in our previous 
experiments, but this effect was not reversed by L-NAME at 
the concentrations tested (Table 4). 
Discussion 
The present study performed with cultured rat anterior 
pituitary cells shows that IL-lp and TNFcv had an inhibitory 
effect on TSH release during both short and long term ex- 
posures, whereas this effect was not observed when IL-lp 
and TNFa were added together with 100 nM TRH. The de- 
crease in TSH release could not be explained by elevated 
cellular T, or T, uptake or by increased nuclear binding of T, 
in the presence of IL-l/3. Furthermore, the effect of IL-lp was 
specific for the thyrotropic cells, as the release of other pi- 
tuitary hormones was not affected. 
An inhibitory effect of cytokines on TSH release from 
cultured anterior pituitary cells was previously described 
(19). On the other hand, other studies with similar cell prep- 
arations reported an increase (24) or no effect (36). The rea- 
sons for these discrepancies are not clear. However, a re- 
duction of TSH release by cytokines irl Gtro seems to be more 
consistent with the changes observed in thyroid parameters 
after cytokine administration in zlizlo (S-10). 
Exposure to IL-lb resulted in a decrease in TSH release, 
which could not be explained by an increased intracellular T, 
concentration in the pituitary. Also, in z,izIo observations sug- 
gested that the effects of IL-l/3 were independent of thyroid 
hormone uptake, as administration of IL-l/3 to hypothyroid 
rats resulted in a decrease in serum TSH (37). 
A question that should be addressed is whether the effect 
on TSH release is due to the exogenously added IL-l/3 or to 
endogenous compounds such as cytokines produced in the 
pituitary after exposure to IL-lb. Local production of IL-l/3 
(23) and IL-6 (38,39) in the pituitary has been demonstrated. 
The same studies showed that IL-lfl is able to induce the 
production of both IL-l and IL-6. Therefore, it is not excluded 
that the effect of IL-l/3 observed in our study derives from 
locally produced IL-l/3 or IL-6 triggered by the exogenous 
TABLE 4. Effect of IL-l/1: alone or combined with L-NAME on 
TSH release during 4-h exposure 
Exp condltims TSH rulcase cne, 
Effect 
cv , 
No additions (17) 
100 piV IL-lb (17) 
100 phi IL-lb + 
0.05 m&l L-NAME (12) 
100 pnr IL-1p + 
0.5 rnM L-NAME (12) 
100 n%f TRH (9) 
., 
11.06 + 0.41 
6.81 ? 0.47” ~38 
6.92 5 0.36” 37 
7.15 5 0.53” -35 
16.15 + 0.43” +46 
Data show the mean t SE of 9-l 7 observations from 2 experiments. 
Anterior pituitary cells (600,000 cells/well) were cultured for 3 days 
in medium containing 10% FCS. Then, culture medium was removed, 
and cells were incubated for 4 h in medium without or with II,-lp (100 
pi) in the absence or presence of the NO synthase inhibitor L-NAME 
(0.05 and 0.5 mM). TSH was measured by RIA. 
I’ P < 0.05 US. no additions. 
IL-l@. The possibility of a role for IL-6 as a mediator of the 
inhibitory effect of IL-lb on TSH release has been suggested 
by two in z~iijo studies in which administration of IL-6 di- 
minished serum TSH levels (10, 12). Furthermore, the facts 
that serum IL-1 levels are low and only slightly elevated in 
severe states of illness (21, 22) and that cytokines exert their 
effects mainly locally favor the concept of locally produced 
cytokines affecting TSH release. 
In a previous irl zlizw study (12), infusion of rats with IL-la 
resulted in greater inhibitory effects on plasma thyroid hor- 
mone and TSH levels than those produced by IL-6. Further- 
more, infusion of IL-la, but not IL-6, resulted in an increase 
in serum corticosterone. The question was raised whether the 
difference in the effects of IL-1 LY and IL-6 on TSH serum levels 
could be explained by an additional effect of corticosterone 
on the thyrotropic cells. In our ill zlifro study, we found an 
inhibitory effect of dexamethasone on basal TSH release. 
Dexamethasone was previously found to reduce GH release 
by cultured anterior pituitary cells at similar concentrations 
(40). Octreotide, a somatostatin analog, also reduced basal 
TSH release during long term exposure, an effect that has 
been described previously (41, 42). 
Although IL-IF affected basal TSH release, this effect dis- 
appeared in the presence of excess amounts of TRH. This 
could mean that excess TRH overruled the effect of IL-1 p or 
that TRH-induced TSH release is regulated differently from 
basal TSH release. Furthermore, it is not excluded that there 
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is an effect of IL-lp on TRH-induced TSH release at sub- 
maximal concentrations of TRH. On the other hand, TNFQ 
was recently reported to stimulate TSH release at submaxi- 
mal concentrations of TRH (19). For dexamethasone, the 
same effect as that for IL-lp was observed, whereas exposure 
to octreotide reduced TRH-induced TSH release by 70(X,, an 
effect that has been observed in previous irl ~~itro studies 
(43-45). The lack of IL-l/3 to affect TRH-induced TSH release 
together with the inhibitory effect of octreotide and the ob- 
servation that IL-l/3 can stimulate the release of hypotha- 
lamic somatostatin (46) suggest an additional suprahy- 
pophysial action of IL-lp irl ZJ~ZW. 
Furthermore, to exclude the possibility that the effect of 
IL-1p on basal TSH release was due to a general action on the 
pituitary, we measured the release of other pituitary hor- 
mones in the presence of IL-l/3. IL-lj3 did not alter ACTH 
release, whereas CRF significantly enhanced it. In previous 
studies using comparable concentrations of IL-l& conflicting 
results on ACTH release were reported, with both a stimu- 
latory effect (24,47) and no effect (48-50) found. Also, we did 
not find any effect of the higher IL-l/3 concentrations (lo-100 
PM) on the release of PRL, FSH, or LH, and this was in 
agreement with previous studies (47, 50). However, our 
study showed an as yet unexplained decrease in FSH and LH 
release at the lowest IL-lp concentration (1 pM). 
Evidence exists that there is a functional link between IL-1 
and NO, the product of oxidation of L-arginine to L-citrulline 
catalyzed by NO synthetase (51, 52). NO synthase activity 
has been observed in the cells of the anterior pituitary tumor 
cell line AtT-20/D16 (53), in the posterior pituitary of rats, 
and in nuclei of rat hypothalami closely associated with the 
regulation of pituitary activity (54). Therefore, a role for NO 
as a mediator of IL-1 action in the neuroendocrine system has 
been suggested. However, in our experiments this seemed to 
be of minor importance, because the effects of IL-lb on TSH 
release could not be reversed by the NO synthase inhibitor 
L-NAME. 
Another possible mediator of the effect of IL-lp could be 
nerve growth factor (NGF). NGF immunoreactivity and NGF 
receptors were recently detected in thyrotropic and other 
anterior pituitary cells (55). Furthermore, IL-lp (1 nM) was 
able to stimulate NGF secretion (25). Together, these findings 
suggest that thyrotrophic cells can be the target of NGF action 
and that the effect of IL-lp can be mediated by locally pro- 
duced NGF, which acts in an auto- or paracrine fashion on 
TSH release. 
The present study shows an inhibitory effect of IL-lp on 
TSH release ill vitro that is in agreement with the decrease in 
the serum TSH level observed after the administration of 
IL-lp irl zko. Thus, our findings support the postulated role 
of IL-1 as a mediator of the changes observed in serum 
thyroid hormone parameters during NTI. From our study it 
can be concluded that the decrease in TSH release can be 
explained by a direct effect of IL-l/3 on the thyrotrophic cells. 
The decrease in TSH release is not due to elevated thyroid 
hormone uptake, increased T, nuclear occupancy, or pro- 
duction of NO. Thus, the mechanism by which IL-lp exerts 
this effect remains to be established. 
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